Evidence map›Paper›PMID 41634241›Full record

ArticleInterdisciplinary sciences, computational life sciences2026

GATRSyn: Advancing Anticancer Drug Synergy Prediction Through Graph Attention Networks and Transformer-based Feature Re-embedding.

Sile Li, Ziyu Li, Chenyang Dong, Yushuang Li

Abstract read
PubMed Publisher
In one paragraph

Article in Interdisciplinary sciences, computational life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sile LiSchool of Science, Yanshan University, Qinhuangdao, 066004, China.
Ziyu LiSchool of Science, Yanshan University, Qinhuangdao, 066004, China.
Chenyang DongSchool of Science, Yanshan University, Qinhuangdao, 066004, China.
Yushuang LiSchool of Science, Yanshan University, Qinhuangdao, 066004, China. yushuangli@ysu.edu.cn.ORCID http://orcid.org/0000-0001-6387-6016

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The integration of deep learning with prior knowledge and multi-omics data enables precise synergy prediction of anticancer drug combinations. However, substantial computational and storage requirements challenge deep learning in managing extensive datasets and multi-scenarios. This study proposes a generalized two-stage framework to address this issue. It decomposes the drug synergy prediction into two key modules: offline feature extraction and multi-scenario adaptive prediction. By integrating drug-cell-associated protein-protein interaction networks with pharmacogenomics data, we first employ an edge-augmented GAT to construct powerful offline feature extractors for drugs and cell lines concurrently, which identify their shared patterns. Next, Transformer-based re-embedding is designed to fine-tune offline features online, which captures cross-modal interactions between specific drugs and cell lines. It can serve as a portable module to seamlessly integrate into various predictive modules. Under this framework, we develop GATRSyn, a dedicated two-stage model for multi-scenario drug synergy prediction. Compared to state-of-the-art deep learning models across multiple high-throughput screening datasets, GATRSyn achieves optimal or near-optimal results across eight distinct prediction scenarios. GATRSyn also effectively screens clinically validated or literature-reported synergistic drug combinations lacking measured scores. Moreover, synergy analysis of eight representative samples and enrichment analysis of pivotal proteins of cell lines and drugs highlights GATRSyn’s ability to model and elucidate targeted therapeutic efficacy of drug combinations against intracellular signaling nodes. Our framework enhances large-scale, multi-scenario drug synergy prediction and provides a comprehensive reference for individualized anticancer treatment.

Indexed as

Anticancer drug combinationCell lineGATProtein-protein interaction networkSynergy predictionTransformer

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.